06/07/22 A Philadelphia life sciences company spun out of a University of Pennsylvania research lab is emerging from stealth mode with nearly $10 million from a seed funding round.
05/03/22 Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced the completion of its $100 million Series A financing led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company, with participation from additional investors including Wedbush Healthcare Partners and founding investors Fairmount, Tellus BioVentures, and Venrock Healthcare Capital Partners.
12/09/21 Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced that the US Patent and Trademark Office (USPTO) has granted U.S. patent number US11191784, titled “The Methods and Composition for Gene Delivery Using an Engineered Viral Particle.”
We make select early investments at the Seed stage in private biotech ventures as the lead or sole investor and participate in Series-A investments.
We launch and fund de novo companies to advance important innovations that may otherwise lack the proper resources to progress efficiently.
Approach & portfolio
